Retiring David Eatwell helped to 'build Genmab into antibody innovation powerhouse'

1 November 2019

Genmab (OMX: GEN), one of the world’s most notable biotech success stories of recent years, has announced that one of those who helped to drive its rapid growth is to retire.

David Eatwell, who has been the chief financial officer at the oncology specialist since 2008, is to retire on February 29, 2020, with Anthony Pagano, currently Genmab’s senior vice president for finance and corporate development, taking over the role.

The Danish company will also start a search to add a fourth executive position for an executive vice president and chief operating officer, who will oversee the commercial, business development and information technology functions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK